| | | - 1 |
|--|--|-----|
| | | ļ |
| | | |
| | | - 1 |
| | | |
| | | - 1 |
| | | |

| 7 (0.0) | n PTO-1449 | | . – | | | ATTY. DOCKET NO. | | SERIAL NO. | | Sheet 1 of | | |
|------------|-------------------------------|----------|--|--|---|--|--|--|--|--------------------|--|--|
| 3/90) | | | | | | 674542-2004 | . 08 | /955,373 | | | | |
| | LIST O | REFER | ENCES CITED BY APP | CPTE | | APPLICANT | _ | · · · · · · · · · · · · · · · · · · · | | | | |
| | • | (Use sev | eral sheets if necessary |)`` ~ 4g | | • | Mourit | sen et al. | | | | |
| | | | (0 | CT 10.2006 | ") | FILING DATE | GROUP | | | | | |
| | | | 3 | | | October 21, 19 | | 1644 | | | | |
| | | | | PAREN | U.S. PAT | ENT DOCUMENTS | | | | | | |
| XAMINER | | DO | CUMENT NUMBER | DATE | | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | | | |
| MTIAL (YS) | | + | | | | | | | | | | |
| 72/ | AA | 5,928 | ,044 | 7/27/1999 | Russell | | | | | | | |
| | T T | DOG | CUMENT NUMBER | DATE | JREIGN P | ATENT DOCUMENTS COUNTRY | 67.450 | 7 | | | | |
| | | | | 5/112 | | COONIKI | CLASS | SUBCLASS | | <u> </u> | | |
| 1891 | AB | WO 9 | 1/16683 | 10/31/1991 | WIPO | ` | + | | TES | TRANSLATION YES NO | | |
| | | | o | THER PRIOR ART | Γ (Including | Author, Title, Date, Pertinent Page | s, Etc.) | | | i | | |
| (h) | AC | | | | | | | 13(2):52-55. | | | | |
| 16) | AD | | Ettinger, H.M. "Carrier sequence selection – one key to successful vaccines." Immunology Today 1992, 13(2):52-55. Dalum, I. et al., "Induction of Cross-reactive antibodies against a self protein by immunization with a modified self protein containing a foreign T helper epitope." Molecular Immunology 1997, 34(16-17):1113-1120. | | | | | | | | | |
| (M) | AE | | Dalum, I. et al., "The | et al., "Therapeutic antibodies elicited by immunization against TNF-ct." Nature Biotechnology 1999, 17:666-669. | | | | | | | | |
| Ver) | AF | | Hertz, M. et al., "Active vaccination against IL-5 bypasses immunological tolerance and ameliorates experimental asthma." The Journal of Immunology 2001, 167:3792-3799. | | | | | | | | | |
| | AG- | | | ging therapeutic va | accines." L | Drug Discovery World 2000, Surmix | 2749-11 | ······································ | nostio | w) . | | |
| INAS A | AH | | Hertz M. et al. "A the | | vaccine ind | ses dentralizado antica ANEC | | s bone loss in evariente | Por tion not | | | |
| | | | - Annual Meeting A | | (| | | | | | | |
| (log) | AI | | Juji, T., et al., "A now | d therapeutic vacci | ne that pre | | in models of oster | porosis and RA. ASE | MR 23 rd Annu | al Meeting | | |
| TON TON | | | Juji, T., et al., "A now Abstracts, page \$223. | ol therapeutic vacci | | vente pathological bone destruction | | | | al Meeting O C | | |
| (4) | AJ | | Juji, T., et al., "A now Abstracts, page \$223. March 6, 2000 Press R | elease from M & E | Biotech. | "M & E Biotech licenses Autovac | M technology to S | chering-Plough Animal | Health." | οÇ | | |
| (67) | | | Juli, T., et al., "A now Abstracts, page \$223. March 6, 2000 Press R April 17, 2000 Press R | elease from M & E | Biotech. | "M & E Biotech licenses Autovac T | technology to S | chering-Plough Animal | Health." | οÇ | | |
| (0) | AJ AK | | Abstracts, page \$223. March 6, 2000 Press R April 17, 2000 Press R May 31, 2000 Press Re | elease from M & E | Biotech. | "M & E Biotech licenses Autovac | technology to S ck A/S/ enter into | chering-Plough Animal a research and develo | Health." | o¢ | | |
| (W) | AJ AK AL | | Juli, T., et al., "A now Abstracts, page \$223. March 6, 2000 Press R April 17, 2000 Press R May 31, 2000 Press Re April 12, 2002 Press Re project." | elease from M & E | Biotech. "Biotech. "Biotech. " | "M & E Biotech licenses Autovac The Biotech A/S and H. Lundbe Offer of shares in M & E Biotech surprise that GlaxoSm | technology to S ck A/S/ enter into abscribed 3 times. ithKline has exclu | chering-Plough Animal a research and develop " usive option on HER-2 | Health." | o¢ | | |
| (10) | AJ AK AL AM | | Abstracts, page \$223. March 6, 2000 Press R April 17, 2000 Press R May 31, 2000 Press Re April 12, 2002 Press Re project." | elease from M & E elease from M & E elease from M & E | Biotech. "Biotech. "Biotech. "Biotech. "Biotech. "Biotech. "Diotech. "Pl | "M & E Biotech licenses Autovac " "M & E Biotech A/S and H. Lundbe Offer of shares in M & E Biotech su Pharmexa announces that GlaxoSm | technology to S ck A/S/ enter into abscribed 3 times. ithKline has exclu- breast cancer in D | chering-Plough Animal a research and develop sive option on HER-2 | Health." pment agreeme | o Cent." | | |
| (0) | AJ AK AL AM | | July, T., et al., "A now Abstracts, page \$223. March 6, 2000 Press R April 17, 2000 Press Re May 31, 2000 Press Re April 12, 2002 Press Re project." July 9, 2001 Press Rele August 1, 2002 Press R | elease from M & E | Biotech. "Biotech. "Biotech. "Pl Biotech. "Pl Biotech. "Pl Biotech. "Pl | "M & E Biotech licenses Autovac The Biotech A/S and H. Lundbe Offer of shares in M & E Biotech surprises that GlaxoSm arrnexa initiates phase I/II trials in the Pharmexa presents important pre-cli | technology to S ck A/S/ enter into abscribed 3 times. ithKline has exclu- breast cancer in D inical data in its A | chering-Plough Animal a research and develop ssive option on HER-2 emmark." | Health." protein breast of the street of th | of cancer. | | |
| (10) | AJ AK AL AM AN AN | | July T. et al., "A now Abstracts, page \$223. March 6, 2000 Press R April 17, 2000 Press Re May 31, 2000 Press Re April 12, 2002 Press Re project." July 9, 2001 Press Rele August 1, 2002 Press R | elease from M & E ase from M & E sess from M & E elease from M & E | Biotech. "Biotech. "Biotech. "Pl Biotech. "Pl Biotech. "Pl Biotech. "Pl Biotech. " | "M & E Biotech licenses Autovac " "M & E Biotech A/S and H. Lundbe Offer of shares in M & E Biotech su Pharmexa announces that GlaxoSm | technology to S ck A/S/ enter into abscribed 3 times. ithKline has exclu- breast cancer in D inical data in its A pre-clinical data | chering-Plough Animal a research and develop " usive option on HER-2 enmark." AutoVac TM HER-2 brea in its AutoVac TM ILS a | Health." protein breast of the state of the | of cancer. | | |
| | AJ AK AL AM AN AO AP | | July, T., et al., "A now Abstracts, page \$223. March 6, 2000 Press R April 17, 2000 Press Re May 31, 2000 Press Re April 12, 2002 Press Re April 12, 2002 Press Re July 9, 2001 Press Rele August 1, 2002 Press R September 20, 2001 Pre | el therapeutic vacci (Abstract) elease from M & E elease from M & E elease from M & E ase from M & E B elease from M& E elease from M& E ses Release from M | Biotech. "Biotech. "Biotech. "Photech. "Photech. "Photech. "I & E Biotech. "E | "M & E Biotech licenses Autovac " "M & E Biotech A/S and H. Lundbe Offer of shares in M & E Biotech su "Pharmexa announces that GlaxoSm tarmexa initiates phase I/II trials in b Pharmexa presents important pre-cl. "Pharmexa publishes important | technology to S bek A/S/ enter into abscribed 3 times. athKline has exclusive ast cancer in D inical data in its A pre-clinical data rial in breast cancer | enmark." AutoVac TM HER-2 breating the AutoVac TM ILS a | Health." protein breast of the state of the | of cancer. | | |
| | AJ AK AL AM AN AO AP AQ | | July, T., et al., "A now Abstracts, page \$223. March 6, 2000 Press R April 17, 2000 Press Re May 31, 2000 Press Re April 12, 2002 Press Reproject." July 9, 2001 Press Rele August 1, 2002 Press R September 20, 2001 Pre September 24, 2001 Pre | elease from M & E ses Release from M & E elease from M elease from M ess Release from M ess Release from M | Biotech. "Biotech. "Biotech. "Biotech. "Biotech. "Biotech. "Pl Biotech. "Biotech. "E Biotech. "& E Biotech. "E Biotech. "E Biotech. "E Biotech. "E Biotech. "Biotech. | "M & E Biotech licenses Autovac The M & E Biotech A/S and H. Lundber Offer of shares in M & E Biotech surprises that GlaxoSm arrnexa announces that GlaxoSm arrnexa initiates phase I/II trials in the Pharmexa presents important pre-cl. ch. "Pharmexa publishes important ch. "Pharmexa publishes important ch. "Pharmexa publishes important ch. "Pharmexa publishes important ch. "Pharmexa publishes phase I/II trials in the pharmexa publishes important ch. "Pharmexa publishes important ch. "Pharmexa publishes phase I/II trials in the pharmexa publishes important ch. "Pharmexa publishes phase I/II trials in the pharmexa publishes important ch. "Pharmexa publishes phase I/II trials in the pharmexa publishes important ch. "Pharmexa publishes phase I/II trials in the pharmexa publishes important ch. "Pharmexa publishes ch. "Pharme | technology to S ck A/S/ enter into abscribed 3 times. ithKline has exclu- breast cancer in D inical data in its A pre-clinical data rial in breast cancer | chering-Plough Animal a research and develop " usive option on HER-2 enmark." AutoVac TM HER-2 bree in its AutoVac TM ILS a er in the United Kingdo | Health." protein breast of the state of the | of cancer. | | |
| | AJ AK AL AM AN AO AP AQ AR | | July T. et al., "A now Abstracts, page \$223. March 6, 2000 Press R April 17, 2000 Press R May 31, 2000 Press Reproject." July 9, 2001 Press Rele August 1, 2002 Press R September 20, 2001 Pre September 24, 2001 Pre December 17, 2001 Pre | el therapeutic vacci (Abstract) elease from M & E elease from M & E elease from M & E ase from M & E B elease from M& E ess Release from M ss Release from M ss Release from M ss Release from M ss Release from M | Biotech. "Biotech. "Biotech. "Biotech. "Pl Biotech. "Pl Biotech. "E Bioteck. "E Bioteck. E Bioteck. E Bioteck. E Bioteck. E Bioteck. E Bioteck. | "M & E Biotech licenses Autovac The M & E Biotech A/S and H. Lundber Offer of shares in M & E Biotech surprise announces that GlaxoSm arrnexa initiates phase I/II trials in the Pharmexa presents important pre-clich. "Pharmexa publishes important ch. "Pharmexa initiates phase I/II trials in the "Pharmexa publishes important ch. "Pharmexa announces AutoVac th. "Positive change in Pharmexa's the tryptic core of the human charior | technology to S ck A/S/ enter into abscribed 3 times. ithKline has exclu- breast cancer in D inical data in its A pre-clinical data rial in breast cancer "" cancer license collaboration with nic gonadotropin to | chering-Plough Animal a research and develop " usive option on HER-2 enmark." AutoVac TM HER-2 bree in its AutoVac TM ILS a er in the United Kingdo option." th Schering-Plough Anim | Health." protein breast of the state of the | cancer. | | |
| | AJ AK AL AM AN AO AP AQ AR AS | | July T. et al., "A now Abstracts, page \$223. March 6, 2000 Press R April 17, 2000 Press Re April 12, 2002 Press Re April 12, 2002 Press Re project." July 9, 2001 Press Rele August 1, 2002 Press R September 20, 2001 Pre September 24, 2001 Pre December 17, 2001 Pre December 19, 2001 Pre Birken, S. et al., Struct 666. (Abstract) | elease from M & E ss Release from M ess Release from M es | Biotech. "Biotech. "Biotech. "Pl Biotech. "Pl Biotech. "Pl Biotech. "Pl & E Biotec & E Biotec & E Biotec | "M & E Biotech licenses Autovac " "M & E Biotech licenses Autovac " "M & E Biotech A/S and H. Lundbe Offer of shares in M & E Biotech st Pharmexa announces that GlaxoSm arrnexa initiates phase I/II trials in t Pharmexa presents important pre-cl ch. "Pharmexa publishes important ch. "Pharmexa initiates phase I/II tr ch. "Pharmexa announces AutoVac ch. "Positive change in Pharmexa's the tryptic core of the human cherior i were well- | technology to S ck A/S/ enter into abscribed 3 times. ithKline has exclusive and the second or a sec | enmark." AutoVac TM HER-2 bree in its AutoVac TM ILS a er in the United Kingdo option." A Schering-Plough Anir Mer-subunit." Endocria. | protein breast of the state of | cancer. | | |

SERIAL NO.

| | | | | | | 674542-200 | 4 | 08 | 3/955,373 | _ |
|-------------|---------------------------------------|--|---|--|--|------------------|------|-------|-----------|---|
| | LIST OF REFERENCES CITED BY APPLICANT | | | | APPLICANT | | | | | |
| | (Use several sheets if necessary) | | | | | Mouritsen et al. | | | | |
| | | | | | | FILING DATE | | GROUP | | |
| けんからり | | | • | | | October 21, | 1997 | 1644 | | |
| | | OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | |
| | | ΑV | | Gerry, E. and Conway, T.P. "Advantage of 1984, 68(1-2)-131-135. (Abstract) | tage of monoclonal vs. polyclonal antisera in a beta 2-microglobulin radioinummoassay." J. Immunological Methods | | | | | |
| | | AW | | Fabian, H. et al., "Comparative analysis of human and Dutch-type elzheimer beta-amyloid peptides by infrared spectroscopy and circular dichroism." Biochem. Biophys. Res. Comm. 1993, 191(1):232-239. (Adstract) | | | | | | |
| 43v | | AX | | Lamba, O.P. et al., "Estimation of the secondary structure and conformation of bovine lens crystallins by infrared spectroscopy: quantitative analysisand resolution by Fourier self-deconvolution and curve fit." Biochim. Biophys. Acta. 1993, 1163(2):113-123. (Abstract) | | | | | | |
| 5 (| | AY | | Klaus, W. and Schomburg, D. "Solution structure of a variant of human pancreatic secretory typisin inhibitor determined by nuclear magnetic resonance spectroscopy." J. Molecular Biology 1993, 229(3):695-706. | | | | | | |
| reter | | | | | | | | | | |
| d esewas | EXAMINER | | | | | DATE CONSIDERED | 1/6 | 107 | | |
| | | | | idered, whether or not citation is in conformationsidered. Include copy of this form with ne | | | | | | |

Based on Form PTO-1449

(3/90)

ATTY, DOCKET NO.

.00068598